Related Experiment Videos
[A clinical study of cisplatin ototoxicity]
C Frade González1, J L Gómez González, C Pescador Mesonero
1Servicio de ORL, Hospital Clínico Universitario, Salamanca.
Acta Otorrinolaringologica Espanola
|January 1, 1990
Summary
Cisplatin (CDDP) chemotherapy can cause hearing loss. This audiological study found that 50% of patients treated with cisplatin experienced ototoxicity.
Area of Science:
- Ototoxic effects of chemotherapy agents
- Audiological assessment in clinical trials
- Nephrotoxic and ototoxic drug monitoring
Context:
- Cisplatin (CDDP) is a widely used chemotherapeutic agent.
- Ototoxicity is a known potential side effect of CDDP treatment.
- Monitoring hearing function is crucial for patients undergoing CDDP therapy.
Purpose:
- To evaluate the ototoxicity of cisplatin (CDDP) in patients undergoing chemotherapy.
- To assess hearing function changes throughout multiple cycles of CDDP treatment.
- To determine the incidence of ototoxicity associated with CDDP.
Summary:
- An audiological study was conducted on 18 patients receiving 4 cycles of CDDP.
- Hearing tests were performed before, during, and after treatment.
- Ototoxicity was identified in 50% of the study participants.
Impact:
- Highlights the significant risk of hearing damage from cisplatin.
- Emphasizes the need for routine audiological monitoring in patients on CDDP.
- Informs clinical practice regarding the management of CDDP-induced ototoxicity.